China’s transgenic animal models provider Cyagen Biosciences has raised 285 million yuan ($41 million) from CMS Capital, Grower Venture Capital, GF Qianhe and GF Investment. In a separate development, Alibaba-backed Amwise has secured $10 million in its Series B round led by Simcere Medical Diagnosis.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com